Ceftriaxone, Ampicillin-Sulbactam Show Similar Outcomes

A retrospective study of older adults with pneumonia found the two antibiotics comparably effective for mortality.

Updated on Nov. 11, 2026 in Asthma

Isometric editorial illustration of two plain amber vials and two clear drip bags side by side on a chrome stand, evoking a balanced comparison of two antibiotic treatments.
A retrospective study of 4,352 U.S. adults over 65 found ceftriaxone and ampicillin-sulbactam produced similar 30-day mortality for pneumonia, with a 13.5% overall death rate. AI Illustration. Upload story photo >

A retrospective study of 4,352 adults older than 65 with community-acquired pneumonia found ceftriaxone and ampicillin-sulbactam produced similar mortality outcomes. The overall 30-day mortality rate was 13.5%, with the difference between the two treatments not statistically significant.

Why it matters

Pneumonia causes higher morbidity and mortality in older adults, and head-to-head comparative data for these two recommended treatments in this population had been limited. The findings add evidence on treatment choice for a high-risk group across U.S. hospitals.

In a retrospective single-center study of 4,352 adults over 65, 30-day mortality was 12.68% with ceftriaxone versus 14.38% with ampicillin-sulbactam, an odds ratio of 1.16 that was not statistically significant. Whether these results hold across other centers remains unestablished by this design.

The players

IDWeek

IDWeek is an annual scientific meeting of infectious disease professionals, including clinicians, researchers and public health experts, where new studies are presented.

The details

Researchers identified patients through discharge diagnoses, comparing 2,176 patients treated with ceftriaxone and 2,176 treated with ampicillin-sulbactam. Older age and higher CURB-65 scores were associated with increased 30-day mortality in both groups, while antimicrobial therapy within 8 hours of diagnosis was associated with lower overall mortality risk.

Timeline

  1. Results were presented at the IDWeek 2026 Annual Meeting.

Health Landscape

The study addresses a gap in comparative evidence for two antibiotics that the Infectious Diseases Society of America recommends for community-acquired pneumonia. Its findings speak to how older adults, who face higher pneumonia morbidity and mortality, are treated under those existing recommendations.

Clinicians treating older adults with pneumonia may weigh these findings when choosing between the two antibiotics, which the study found to have similar mortality outcomes. Patients and families should discuss treatment options with their physicians, since the study's retrospective single-center design limits how broadly its results can be applied.

The takeaway

Among older adults with pneumonia in this study, ceftriaxone and ampicillin-sulbactam performed similarly, and earlier antimicrobial treatment within 8 hours of diagnosis was linked to lower mortality. Readers should treat the findings as one retrospective data point rather than a final treatment standard.

Further reading

For more on respiratory conditions, see Asthma coverage in the United States.

Source note: This article includes information reported by Medscape.